Explore

Trendline Trendline
Zura Bio Announces Inducement Grants to New Employees Under Nasdaq Rule

Zura Bio Announces Inducement Grants to New Employees Under Nasdaq Rule

Zura Bio Announces Inducement Grants to New Employees Under Nasdaq Rule
Trendline Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement

Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement

Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement
Trendline Trendline
Lunai Bioworks Completes $20 Million Equity Issuance to Expand CNS Platform

Lunai Bioworks Completes $20 Million Equity Issuance to Expand CNS Platform

Lunai Bioworks Completes $20 Million Equity Issuance to Expand CNS Platform
Trendline Trendline
Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark
Trendline Trendline
Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics

Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics

Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics
Trendline Trendline
Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request

Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request

Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request
Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark
Trendline Trendline
UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers
Trendline Trendline
Rosen Law Firm Urges Atara Biotherapeutics Investors to Join Securities Class Action Before Deadline

Rosen Law Firm Urges Atara Biotherapeutics Investors to Join Securities Class Action Before Deadline

Rosen Law Firm Urges Atara Biotherapeutics Investors to Join Securities Class Action Before Deadline